Quantum Cyber N.V. (QUCY) Stock Price & Analysis

Quantum Cyber N.V. (QUCY) rose 0.00% to USD 1.08 as of July 25, 2026 at 03:05 UTC, according to Nexqual real-time market data.

QUCY last closed at USD 1.08; the session ranged USD 1.08–1.14 on volume of 574,555 shares. Market capitalization is —, with a 52-week range of USD 0.3–4.93 (NCM). Source: Nexqual, July 25, 2026 at 03:05 UTC.

Key Statistics (as of July 25, 2026 at 03:05 UTC)

Technical Analysis (QUCY)

Nexqual's technical model rates QUCY "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:05 UTC.

From Quantum Cyber N.V.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• In March 2025, we acquired a license from Liquid Bioscience, Inc. to access a portfolio of novel mRNA biomarkers and AI developed proprietary algorithm, for the non-invasive detection of pancreatic cancer with a blood test.
• Our approach integrates proprietary, validated biomarkers with reliable diagnostic tools to optimize accuracy and applicability.
• In the analysis, the biomarkers coupled with the proprietary algorithm developed by Liquid, achieved overall sensitivity of 95% and a 98% specificity for the detection of pancreatic cancer.
•   General   Historically, we have developed and sold in-vitro diagnostic ("IVD") tests for the early detection of cancer.

Partnerships

• Through our agreement with the Université de Sherbrooke, we obtained an exclusive, unilateral option to acquire a license for the UdeS Biomarkers.
• Enabling earlier detection of these diseases allows for earlier and better therapy for affected individuals.   1     Pancreatic Cancer Screening Tests   In March 2025, the Company entered into an Agreement with Liquid Biosciences.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:05 UTC. This page is informational and not investment advice.